METHODS: RNA sequencing results (GSE267388 and GSE79962) were used for cross-species integrative analysis. Bioinformatic analyses were used to delve into function, tissue- and cell- specificity, and interactions of genes. External datasets and qRT-PCR experiments were used for validation. L1000 FWD was used to predict targeted drugs, and 3D structure files were used for molecular docking.
RESULTS: Based on bioinformatic analyses, ten differentially expressed genes were selected as genes of interest, seven of which were verified to be significantly differential expression. Bucladesine was considered as a potential targeted drug for SIMD, which banded to seven target proteins primarily by forming hydrogen bonds.
CONCLUSIONS: It was considered that Cebpd, Timp1, Pnp, Osmr, Tgm2, Cp, and Asb2 were novel disease genes, while bucladesine was a potential therapeutic drug, of SIMD.
方法:RNA测序结果(GSE267388和GSE79962)用于跨物种整合分析。生物信息学分析用于深入研究功能,组织和细胞特异性,和基因的相互作用。外部数据集和qRT-PCR实验用于验证。L1000FWD用于预测靶向药物,和3D结构文件用于分子对接。
结果:基于生物信息学分析,十个差异表达的基因被选为感兴趣的基因,其中7个被证实为显著差异表达。Bucladesine被认为是SIMD的潜在靶向药物,主要通过形成氢键与七种靶蛋白结合。
结论:有人认为Cebpd,Timp1,Pnp,Osmr,Tgm2,Cp,和Asb2是新的疾病基因,而bucladesine是一种潜在的治疗药物,SIMD。